Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEED-PD: Expanding the Therapeutic Window with LDp/CDp in Parkinson's Disease
jRCTs031250636Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoint: Primary: Ratio of threshold plasma levodopa concentration for dyskinesia onset (baseline vs 24 weeks). Started Feb 2026; status: recruiting.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCTs031250636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250636.